Printer Friendly

Dr Reddy's Laboratories unveils US FDA approved Paricalcitol Injection.

M2 EQUITYBITES-September 20, 2016-Dr Reddy's Laboratories unveils US FDA approved Paricalcitol Injection


Pharmaceutical company Dr Reddy's Laboratories (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Monday the availability of Paricalcitol Injection, USP in 2 mcg, 5 mcg, 10 mcg in the US market.

The company said the Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg is the therapeutic equivalent generic version of the US Food & Drug Administration (USFDA) approved Zemplar (paricalcitol) Injection. Zemplar is a registered trademark of ABBVIE Inc.

According to IMS Health, the Zemplar brand and generic had US sales of approximately USD22.5m MAT for the most recent 12 months ending in July 2016.

In conjunction with the launch, the Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product in the US market.

((Comments on this story may be sent to

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 20, 2016
Previous Article:Avanti Communications launches ECO initiative; Announces first ECO contract.
Next Article:Natural Alternatives International achieves higher net income of USD3.4m for Q4 fiscal 2016.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters